Libexin, tablets 100 mg 20 pcs

Prenoxdiazine is an antitussive agent of peripheral action.

The drug Libexin blocks the peripheral links of the cough reflex due to the following effects:

– local anesthetic action, which reduces irritability of peripheral sensitive (cough) airway receptors;

– bronchodilator effect, due to which the stretching receptors, participating in the cough reflex, are inhibited;

– a slight decrease of respiratory center activity (without suppression of respiration). The anti-coughing effect of the drug is approximately equal to that of codeine.

Prenoxdiazine is not addictive and not addictive. In chronic bronchitis an anti-inflammatory effect of Prenoxdiazine has been noted. Prenoxdiazine does not affect CNS function, except for a possible indirect anxiolytic effect.

Indications

Non-productive cough of any origin:

upper respiratory tract catarrh, influenza, acute and chronic bronchitis, pneumonia, emphysema;
night cough in patients with heart failure;
preparing patients for bronchoscopic or bronchographic examination.

Pharmacological effect

Prenoxdiazine is a peripherally acting antitussive.

The drug Libexin blocks the peripheral parts of the cough reflex due to the following effects:

– local anesthetic effect, which reduces the irritability of peripheral sensitive (cough) receptors of the respiratory tract;

– bronchodilator effect, due to which the stretch receptors involved in the cough reflex are suppressed;

– slight decrease in the activity of the respiratory center (without respiratory depression). The antitussive effect of the drug is approximately equal to that of codeine.

Prenoxdiazine does not cause addiction or drug dependence. In chronic bronchitis, the anti-inflammatory effect of prenoxdiazine has been noted. Prenoxdiazine does not affect central nervous system function, with the exception of a possible indirect anxiolytic effect.

Special instructions

The drug may cause gastrointestinal complaints in patients with lactose intolerance, because Each tablet contains 0.38 mg of lactose.

Impact on the ability to drive vehicles and perform work associated with increased danger.

Taking the drug in high doses can slow down the rate of reactions, therefore, when taking the drug in high doses, the question of the possibility of driving a car or engaging in work associated with increased danger should be decided individually.

Active ingredient

Prenoxdiazine

Composition

Active ingredient:

prenoxdiazine hydrochloride 100 mg;

Excipients:

glycerol (glycerol);

magnesium stearate;

talc;

povidone;

corn starch;

lactose monohydrate.

Contraindications

hypersensitivity to the drug;
diseases associated with excessive bronchial secretion;
state after inhalation anesthesia;
galactose intolerance, lactase deficiency or glucose-galactose malabsorption.

With caution: children’s age.

Side Effects

Allergic reactions: rarely – skin rash; angioedema; unknown frequency – bronchospasm.

From the gastrointestinal tract: rarely – dry mouth or throat; anesthesia (temporary numbness and loss of sensitivity) of the oral mucosa; often – pain in the stomach; constipation; nausea.

From the nervous system (when using the drug in high doses): unknown frequency – mild sedative effect; fatigue.

Interaction

It is not recommended to combine the drug with mucolytic and expectorant drugs, because it can impede the release of sputum, which is liquefied by the latter.

There are no preclinical or clinical data on interactions with other drugs.

Storage conditions

At a temperature not exceeding 25 °C.

Shelf life

5 years

Manufacturer

Opella Healthcare Hungary Ltd., Hungary